WebRasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of... WebEvaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy. 2008;28(6):685–690. 23. Rényi I, Bárdi E, Udvardi E, et al. Prevention …
Rasburicase in the management of tumor lysis: an …
WebJun 1, 2011 · It is concluded that a single 3-mg dose of rasburicase, used with close monitoring, is sufficient to treat most adults with uric acid levels up to 12 mg/dL, and continues to decline beyond 24 h in most patients without additional treatment. Rasburicase was administered at a fixed dose of 3 mg to treat 287 episodes of elevated serum uric … WebRasburicase injection is used to treat high levels of uric acid (a natural substance that builds up in the blood as tumors break down) in people with certain types of cancer who … data factory bearer token
Rasburicase - an overview ScienceDirect Topics
WebRasburicase Elitek Antihyperuricemic agent Injection: 1.5, 7.5 mg; contains mannitol and L-alanine Hyperuricemia (all ages): 0.1–0.2 mg/kg/dose (rounded down to the nearest whole 1.5 mg multiple) IV over 30 min × 1. Patients generally respond to one dose but if needed dose may be repeated Q 24 hr for up to four additional doses. WebBackground: Fixed-dose rasburicase (FDR) is common practice in treating hyperuricemia associated with tumor lysis syndrome in adults; however, there is a lack of data regarding the effectiveness of this dosing strategy specifically in the overweight and obese patient populations. Objective: To determine if patient weight per body mass index (BMI) … WebOur results demonstrate that a single fixed dose of rasburicase 3 mg, repeated if required, should be the standard regimen in the management of TLS. Recent studies and published guidelines have shown cumulative … bitmap image to word